Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Polatuzumab · Polivy

Antibody-drug conjugate · Cytotoxic, directed at CD79b · developed by Genentech

Approved FDA
1 Registered trials

What is Polatuzumab?

Polatuzumab vedotin is an antibody-drug conjugate that binds CD79b, a B-cell surface protein of the B-cell receptor, and delivers the anti-mitotic agent MMAE into the cell after internalization. MMAE binds microtubules, inhibiting cell division and inducing apoptosis. It is used in B-cell lymphoma, including diffuse large B-cell lymphoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Polivy
Drug type
Antibody-drug conjugate
Targets
CD79b
Mechanism
Cytotoxic, directed at CD79b
Pathways
microtubule disruption, apoptosis
Therapy area
Oncology
Developer
Genentech, Inc.
In trials of
BMY
FDA status
Approved as Polivy, BLA761121 · FDA label
UNII
ME5E8BU5ST

✅ FDA-approved uses

From the indications section of the FDA label (version of Aug 24, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07917832 Phase 2 Multi Center Not yet recruiting BMY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

B Cell LymphomaG2pGlofitamabGolcadomideMulti CenterPhase 2PolauzumabVedotin

Other drugs acting on CD79B

Sources

Updated Nov 8, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.